Abstract: A switching device including a GaN substrate; an unintentionally doped GaN layer on a first surface of the GaN substrate; a regrown unintentionally doped GaN layer on the unintentionally doped GaN layer; a regrowth interface between the unintentionally doped GaN layer and the regrown unintentionally doped GaN layer; a p-GaN layer on the regrown unintentionally doped GaN layer; a first electrode on the p-GaN layer; and a second electrode on a second surface of the GaN substrate.

Abstract: A p-n diode includes a first electrode, a n-GaN layer on the first electrode, a p-GaN layer on the n-GaN layer, and a second electrode on a first portion of the p-GaN layer. A region of the p-GaN layer surrounding the electrode is a passivated region. Treating a GaN power device having a p-GaN layer includes covering a portion of the p-GaN layer with a metal layer, exposing the p-GaN layer to a hydrogen plasma, and thermally annealing the p-GaN layer, thereby passivating a region of the p-GaN layer proximate the metal layer.

Abstract: The present disclosure provides an antibody, or an antigen binding fragment or variant thereof, which binds to CD27 and exhibits at least one of the following properties: specifically binds to CD27 with a KD of 10?8 M or less; activates and/or increases CD27 mediated NF-?B activity; stimulates CD4+ and/or CD8+ T cell proliferation; binds to human CD27 expressed on a cell surface; stimulates secretion of IFN-? by CD4+ and/or CD8+ T cells. The present disclosure also provides a method for preparing and using said antibody.

Abstract: Provided is an immunoconjugate useful in inhibiting tumor growth, and a composition and/or protein mixture comprising the immunoconjugate. Also provided are methods for the production of the immunoconjugate, as well as pharmaceutical uses of the immunoconjugate in inhibiting tumor growth, including but not limited to treatment of cancers.

Abstract: Fabricating a regrown GaN p-n junction includes depositing a n-GaN layer on a substrate including n+-GaN, etching a surface of the n-GaN layer to yield an etched surface, depositing a p-GaN layer on the etched surface, etching a portion of the n-GaN layer and a portion of the p-GaN layer to yield a mesa opposite the substrate, and passivating a portion of the p-GaN layer around an edge of the mesa. The regrown GaN p-n junction is defined at an interface between the n-GaN layer and the p-GaN layer. The regrown GaN p-n junction includes a substrate, a n-GaN layer on the substrate having an etched surface, a p-GaN layer on the etched surface, a mesa defined by an etched portion of the n-GaN layer and an etched portion of the p-GaN layer, and a passivated portion of the p-GaN layer around an edge of the mesa.

Abstract: A switching device including a GaN substrate; an unintentionally doped GaN layer on a first surface of the GaN substrate; a regrown unintentionally doped GaN layer on the unintentionally doped GaN layer; a regrowth interface between the unintentionally doped GaN layer and the regrown unintentionally doped GaN layer; a p-GaN layer on the regrown unintentionally doped GaN layer; a first electrode on the p-GaN layer; and a second electrode on a second surface of the GaN substrate.

Abstract: A computer aided medical method include following steps. An initial symptom is collected through an interaction interface. A representative prediction model is selected from plural candidate prediction models according to the initial symptom. The candidate prediction models are trained by a machine learning algorithm according to clinical data. A series of sequential actions is generated according to the representative prediction model and the initial symptom. The sequential actions are selected from plural candidate actions in the representative prediction model. The candidate actions include plural inquiry actions and plural disease prediction actions. Each of the sequential actions is one of the inquiry actions or the disease prediction actions. The series of sequential actions is displayed on the interaction interface.

Abstract: A method for preventing or treating a non-alcoholic fatty liver disease in a subject who is at risk of suffering from the non-alcoholic fatty liver disease or suffers from the non-alcoholic fatty liver disease, by administering to the subject a composition comprising a therapeutically effective amount of Antrodins.

Abstract: A computer aided medical method include following steps. An initial symptom is collected through an interaction interface. A representative prediction model is selected from plural candidate prediction models according to the initial symptom. The candidate prediction models are trained by a machine learning algorithm according to clinical data. A series of sequential actions is generated according to the representative prediction model and the initial symptom. The sequential actions are selected from plural candidate actions in the representative prediction model. The candidate actions include plural inquiry actions and plural disease prediction actions. Each of the sequential actions is one of the inquiry actions or the disease prediction actions. The series of sequential actions is displayed on the interaction interface.

Abstract: Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

Abstract: A computer aided medical method includes the following steps. An initial symptom of a patient and context information is collected through an interaction interface. Actions in a series are sequentially generated according to the candidate prediction models and the initial symptom. Each of the actions corresponds to one of the inquiry actions or one of the disease prediction actions. If the latest one of the sequential actions corresponds to one of the disease prediction actions, potential disease predictions are generated in a first ranking evaluated by the candidate prediction models. The first ranking is adjusted into a second ranking according to the context information. A result prediction corresponding to the potential disease predictions is generated in the second ranking.

Abstract: Provided are compositions and methods for treating cancer comprising the use of a immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy. The immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy shows synergistic effects in cancer treatment.

Abstract: A computer aided medical method includes the following steps. An initial symptom of a patient and context information is collected through an interaction interface. Actions in a series are sequentially generated according to the candidate prediction models and the initial symptom. Each of the actions corresponds to one of the inquiry actions or one of the disease prediction actions. If the latest one of the sequential actions corresponds to one of the disease prediction actions, potential disease predictions are generated in a first ranking evaluated by the candidate prediction models. The first ranking is adjusted into a second ranking according to the context information. A result prediction corresponding to the potential disease predictions is generated in the second ranking.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: A switching device including a GaN substrate; an unintentionally doped GaN layer on a first surface of the GaN substrate; a regrown unintentionally doped GaN layer on the unintentionally doped GaN layer; a regrowth interface between the unintentionally doped GaN layer and the regrown unintentionally doped GaN layer; a p-GaN layer on the regrown unintentionally doped GaN layer; a first electrode on the p-GaN layer; and a second electrode on a second surface of the GaN substrate.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Abstract: Provided are a self-service method and device. The method includes: acquiring by a camera video data associated with a shopping cart at a distance from a shelf less than a preset value; determining whether an article is being placed into the shopping cart, based on identification of the video data; if yes, acquiring an ID of the shopping cart, determining the placed article and associating the ID with the article; displaying a total sum of all articles associated with the ID to the user when detecting the shopping cart corresponding to the ID is located in a preset payment area in the shopping mall; and executing a permitting procedure for allowing the shopping cart corresponding to the ID to pass upon reception of a message fed back from the payment area and indicating that the total sum corresponding to the ID has been cleared.

Abstract: Provided are a method and apparatus for identifying a product. The method includes: acquiring an image of the product; performing multilevel detection on the image to determine a label region of the product, specifically, an image region corresponding to a previous level of detection is greater than an image region corresponding to a following level of detection; and identifying information in the label region to determine information of the product. A product can be identified automatically by acquiring the image of the product and performing multilevel detection on the image, thereby efficiency is improved, a large number of products can be handled, and cost is reduced.

Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.